What's new? Log in Free sign up

Precision Biosciences (DTIL) News and press releases

Company Profile

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $17 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $17 price target.

Precision BioSciences Announces Program Updates Across Its Allogeneic CAR T Pipeline

Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T Related Adverse Events

Precision BioSciences Q1 EPS $(0.23), Inline, Sales $8.78M Beat $5.67M Estimate

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.46) per share from the same period last year.

Earnings Scheduled For May 9, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.

Preview: Precision BioSciences's Earnings

Precision BioSciences To Present Preclinical In Vivo Gene Editing Research For Its ARCUS HBV Program At Upcoming Global Hepatitis Summit 2023

Biotech, News, FDA, Events, General

- Oral Presentation to Highlight Efficacy and Specificity of ARCUS Nucleases for Potential Treatment of Chronic Hepatitis BPrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing

Precision BioSciences Announces Late-Breaking Abstract Of Preclinical In Vivo Gene Editing Research Selected For Oral Presentation At The American Society Of Gene & Cell Therapy 26th Annual Meeting

Biotech, News, FDA, Events, General

- Presentation to Highlight Preclinical Development Progress of PBGENE-DMD Program for Potential Treatment of Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing

Precision Biosciences Has Received A Notice Of Allowance From The U.S. Patent And Trademark Office Covering Engineered Meganucleases Specific For Recognition Sequences In The Pcsk9 Gene

Biotech, News, Health Care, General

Once issued, patents arising from these international applications will have standard expiration dates in October 2038, and the U.S. patent arising from the ‘856 application will have a standard expiration date in

Stocks That Hit 52-Week Lows On Friday

On Friday, 469 companies hit new 52-week lows.

HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $17 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $17 price target.

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's morning session saw 84 companies set new 52-week lows.

Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Looking Into Precision BioSciences's Return On Capital Employed

BMO Capital Downgrades Precision BioSciences to Market Perform, Lowers Price Target to $4

News, Downgrades, Price Target, Analyst Ratings

BMO Capital analyst Kostas Biliouris downgrades Precision BioSciences (NASDAQ:DTIL) from Outperform to Market Perform and lowers the price target from $7 to $4.

Precision BioSciences Q4 EPS $(0.26) Misses $(0.21) Estimate, Sales $10.60M Beat $6.81M Estimate

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.21) by 23.81 percent. This is a 29.73 percent increase over losses of $(0.37) per

Earnings Scheduled For March 9, 2023

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.

Preview: Precision BioSciences's Earnings

Press releases

From Benzinga Pro

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward

Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T Related Adverse Events

Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023

Precision BioSciences, Inc. (NASDAQ:DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will share an

Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day

Precision BioSciences, Inc. (NASDAQ:DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will participate

Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting

Late-breaking, oral presentation highlights ability of ARCUS gene editing approach to achieve large gene excisions enabling significant functional muscle improvement in preclinical study Precision BioSciences, Inc.

Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting

Late-Breaking Abstract Demonstrates Capabilities of ARCUS for Large Gene Excision In Vivo Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo

Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update

- Program Updates Planned for Azer-cel and PBCAR19B in May 2023 - Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT Conference - In Vivo Gene

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on April 27, 2023, the

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023

- Oral Presentation to Highlight Efficacy and Specificity of ARCUS Nucleases for Potential Treatment of Chronic Hepatitis B Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing

Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting

- Presentation to Highlight Preclinical Development Progress of PBGENE-DMD Program for Potential Treatment of Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing

Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has received a Notice of

Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference

Precision BioSciences, Inc. (NASDAQ:DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

- Advanced ARCUS Gene Editing Development for Clinical and Research Programs; In Vivo Gene Editing R&D Day Planned for Mid-2023 - Progressed Azer-cel and PBCAR19B Allogenic CAR T Clinical Studies; Program Updates

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.